NCT03809078View on ClinicalTrials.gov

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

March 8, 2022

Study Completion Date

March 8, 2022

Conditions
Prostate Cancer
Interventions
DRUG

68Ga RM2

PET radiopharmaceutical

DRUG

68Ga-PSMA-11

PET radiopharmaceutical

DEVICE

Investigational PET scanner coils and software

GE Healthcare non-approved PET scanner coils and software

Trial Locations (1)

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

General Electric

INDUSTRY

lead

Andrei Iagaru

OTHER

NCT03809078 - 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer | Biotech Hunter | Biotech Hunter